<DOC>
	<DOC>NCT00351130</DOC>
	<brief_summary>Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor. A patient non compliant to drug therapy is recognized as one of the primary reasons for inadequate blood pressure control.</brief_summary>
	<brief_title>Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in na√Øve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criteria MSSBP&gt; 140 mm Hg, and/or MSDBP&gt; 90 mm Hg and currently treated with either valsartan 320 mg/ HCTZ 25 mg or amlodipine 10 mg/HCTZ 25 mg at end of core study Exclusion criteria Premature discontinuation in the core study or failure to comply with the core study protocol Any patient that the investigator decides should not participate in the extension Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension,</keyword>
	<keyword>stage 1 hypertension,</keyword>
	<keyword>stage 2 hypertension,</keyword>
	<keyword>valsartan,</keyword>
	<keyword>amlodipine,</keyword>
</DOC>